v3.26.1
Note 2 - Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2026
Notes Tables  
Schedule of Cash and Cash Equivalents [Table Text Block]
  

March 31, 2026

  

December 31, 2025

 

BioLargo, Inc. and subsidiaries

 $2,300  $2,826 

Clyra Medical Technologies, Inc.

  1,822   1,057 

Total

 $4,122  $3,883 
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
  

Three Months Ended March 31,

 
  

2026

  

2025

 

Customer A

  21%  %

Customer B

  17%  %

Customer C

  14%  %

Customer D

  11%  %

Customer E

  %  79%
  

March 31, 2026

  

December 31, 2025

 

Customer A

  22%  %

Customer C

  14%  %

Customer D

  17%  %
Schedule of Inventory, Current [Table Text Block]
  

March 31, 2026

  

December 31, 2025

 

Raw material

 $106  $125 

Finished goods

  186   185 

Total

 $292  $310 
Schedule of Other Assets, Noncurrent [Table Text Block]
  

March 31, 2026

  

December 31, 2025

 

Patents

 $34  $34 

Security deposits

  72   72 

Interest receivable

  2    

Total

 $108  $106 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

2026

  

2025

 
  

Non Plan

  

2024 Plan

  

Non Plan

  

2024 Plan

 

Risk free interest rate

     4.30%  4.23%  4.23 - 4.58%

Expected volatility

     84%  91%  91%

Expected dividend yield

            

Forfeiture rate

            

Life in years

     10   10   10 
Property, Plant, and Equipment [Table Text Block]
  

March 31, 2026

  

December 31, 2025

 

Equipment

 $1,756  $1,724 

Leasehold improvements

  526   526 

Total, at cost

  2,282   2,250 

Less: accumulated depreciation

  (641)  (607)

Total equipment and leasehold improvements, net

 $1,641  $1,643